IL23A and inflammatory bowel disease: Recent studies in patients with severe IBD and those unresponsive to conventional biologics (e.g., anti-TNF and anti-IL-23) have highlighted excessive mucosal necroptosis mediated by RIPK1 and RIPK3 [91].